BD Convenience Kit Early Alert: Sodium Chloride Ampule Checklist

BD Convenience Kit Early Alert: What Wound Centers Should Check Now

FDA's Center for Devices and Radiological Health (CDRH) has issued an Early Alert for various Becton Dickinson (BD) Convenience Kits and Procedure Trays. The affected component is narrow but clinically significant: sodium chloride ampules manufactured by Huons Co., Ltd. and recalled by Elevaris Medical Devices, which BD includes as flush solution inside certain kits. On August 10, BD sent letters to affected customers recommending that the ampules be corrected — removed from the kits — before continued use.

The scope is larger than a single product. The FDA's published list of affected product covers 213 distinct lot numbers across 32 catalog numbers, spanning BD PowerLine (PWRTL) and DOT procedure tray families, with catalog numbers ranging from 5605150 through 5865240. For wound centers and outpatient procedure sites that stock convenience kits for debridement, dialysis access, and vascular procedures, the practical question is not whether this is a headline recall — it is whether anyone on your team has checked the shelf against the lot list yet.

What the Early Alert Actually Says

Three facts define the response:

1. Only the sodium chloride ampule is affected. FDA and BD state that the ampule is the only impacted component, and all remaining components in the kit or tray can continue to be used safely. This is a correction, not a full-kit discard. 2. The risk is sterility compromise of the flush solution. If the sterility of the sodium chloride injection is compromised, patients may be exposed to viable microorganisms, endotoxins, or foreign material generated during manufacturing. The downstream consequences FDA describes — systemic inflammatory response, infection, micro-clots, and organ failure — are the reasons this was flagged as a potentially high-risk device issue. 3. No serious injuries reported to date. As of July 29, BD had not reported any serious injuries or deaths associated with the issue.

This is the latest in a series of component recalls arriving embedded inside convenience kits rather than as standalone notices — a pattern that rewards centers with a standing verification workflow.

A 3-Step Verification Workflow for Clinical and Supply-Chain Staff

Step 1: Identify affected kits in inventory

Pull the FDA's full list of affected product — linked directly from the Early Alert page as a downloadable spreadsheet with product name, catalog number, lot number, UDI, and expiration date. Cross-reference it against:

- Central supply and procedure-room stock - Case carts and procedure trays staged for upcoming cases - Consignment and off-site inventory

Match on catalog number first, then confirm at the lot level. Lot numbers in the affected families begin with the prefixes REK or REL; the catalog-number range (5605150–5865240) is the fastest first-pass filter.

Step 2: Label, quarantine the ampules, and secure alternative flush

BD's August 10 letter recommends labeling all affected kits and trays so products containing the affected ampules are easy to identify — applying labels without covering or obscuring any regulatory or traceability information. Kits should be quarantined until BD-provided over-labels arrive. Critically for procedure scheduling: secure an alternative local sodium chloride supply before entering the procedural environment, so a labeled kit does not become a stalled case.

Step 3: Remove and destroy the ampule at the point of use

Upon opening an affected kit, remove and destroy the sodium chloride ampule within a controlled, sterile environment so the sterility of the remaining components is preserved. Document what was removed, from which lot, in which case — the same lot-level documentation discipline that independent testing and supply-chain verification applies to biologic grafts, and that lot-level traceability also underpins reimbursement and coding for amniotic membrane allografts.

If You Already Used an Affected Ampule

FDA's guidance is proportionate:

- If an affected ampule was previously used without issue, no additional treatment or clinical follow-up is required. - If one was used with an observed issue, report the incident per institutional guidelines and take any necessary clinical actions. - For patients who have already undergone procedures using affected lots, no specific follow-up is required for asymptomatic patients; individuals presenting with adverse health outcomes potentially related to the ampules should seek appropriate medical evaluation.

Record the exposure review in your recall log either way — including the decision not to notify — so the file is complete if FDA guidance evolves.

Why Component-Level Recalls Stress-Test Your Supply Chain

A convenience kit consolidates dozens of components under one manufacturer's label. When a single component — here, a flush ampule sourced from Huons and recalled by Elevaris — triggers action, the burden of lot-level traceability shifts to the end-user facility. The same lesson holds across this year's downstream kit corrections for Huons saline and Spectra sodium chloride flush: the component manufacturer, the kit manufacturer, and the recall authority may all be different entities, while your inventory system tracks only the kit-level catalog number.

Frequently Asked Questions

No. BD recommended a correction: remove the affected sodium chloride ampules and label the kits. All remaining components may continue to be used. FDA classifies this as an Early Alert for a potentially high-risk device issue and is continuing to review information.

Various BD Convenience Kits and Procedure Trays — the PowerLine (PWRTL) and DOT tray families in the FDA's affected-product list, spanning 32 catalog numbers and 213 lots. Verify against the FDA's spreadsheet directly rather than relying on summaries.

If it was used without issue, FDA says no additional treatment or follow-up is required. Asymptomatic patients need no specific follow-up. Anyone presenting with adverse outcomes possibly related to the ampules should seek medical evaluation, and incidents should be reported per your institutional guidelines.

U.S. customers with adverse reactions, quality problems, or questions should contact BD at [email protected] or (844) 823-5433. Adverse events can also be reported to FDA through MedWatch.

Compliance Note

This article is an educational operational advisory for wound center procurement, clinical, and quality staff based on the FDA Early Alert and BD's customer letter as published. It is not legal advice and does not establish a standard of care. Early Alert status, affected lots, and recommended actions may change as FDA's review continues; verify the current FDA notice and manufacturer communications before acting, and follow your institution's recall and risk policies.

References

1. U.S. Food and Drug Administration. Early Alert: Convenience Kit Issue from Becton Dickinson. FDA Medical Device Recalls and Early Alerts. Available at: fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-convenience-kit-issue-becton-dickinson.

2. U.S. Food and Drug Administration. Full List of Affected Product — BD Convenience Kits and Procedure Trays (213 lots across 32 catalog numbers). Available from the Early Alert page above.

3. U.S. Food and Drug Administration. Huons Co., Ltd. Saline and Lidocaine Recall: FDA Enforcement Report. Available at: accessdata.fda.gov.

4. U.S. Food and Drug Administration. Spectra Medical Devices Sodium Chloride Flush Recall: FDA Enforcement Report. Available at: accessdata.fda.gov.

Related Resources

- Quality Assurance for Wound Biologics: Independent Testing and Supply Chain Integrity - Reimbursement and Coding for Amniotic Membrane Allografts: 2026 Update